

Ref: FOI/GS/ID 4596

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

27 March 2018

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to biomarker testing.

You asked:

1. Do you currently offer a biomarker testing for the following, as of the beginning of 2018?

PD-L1 in NSCLC

ALK in NSCLC

BRAF in Melanoma

2. Is predictive biomarker testing conducted at the same lab (or similar location such as in same building) as the initial cytological and histological (H&E stain) assessment, or is this done at a different site?

IHC

FISH /ISH/ NGS / PCR

3. Is biomarker testing performed reflexively or upon request for the following biomarkers?

PD-L1 in NSCLC

ALK for NSCLC

BRAF in Melanoma

4. Which of the following biomarkers are assessed in lung cancer patients in your laboratory? (please select all that apply)

5. Which of the following testing platforms are used at this this laboratory?

6. What IHC staining platform(s) are used in the laboratory for biomarker testing? (please select all that apply)

7. What type of test does the institution prefer to use for biomarker-predictive IHCs?

What is the main factor in this decision?

8. Does your lab / trust seek separate reimbursement from NHS under the "high-cost medicines and tests" provision for biomarker tests that have been excluded from tariff?

9. What is the number of samples being tested (or sent-out) are tested for the following biomarkers?

ALK

EGFR

PD-L1

BRAF

10. Where are archived tissues from lung cancer patients stored?

11. If on-site; how long are tissues stored on site until transferred to other storage facility?

12. What is the typical turn-around time from tissue/specimen extraction to the report of biomarker testing results in lung cancer patients?

13. How are the following biomarker testing funded at your lab?

Trust response:

1. PD-L1 in NSCLC - Yes, but send out PD-L1 testing to another laboratory
(Please specify which laboratory samples are sent to: QEHB)

ALK in NSCLC - Yes, but send out ALK testing to another laboratory
(Please specify which laboratory samples are sent to: QEHB)

BRAF in Melanoma - Yes, in house service

2. IHC - No, sent to another lab or site

(Please specify which laboratory samples are sent to: QEHB)

PCR - Yes, done at same lab or site

3. PD-L1 in NSCLC - Reflexively (i.e. prior to starting 1L treatment)

If reflexively – Multi-marker panel (i.e. multiple biomarkers, one test)

ALK for NSCLC - Reflexively (i.e. prior to starting 1L treatment)

If reflexively – Multi-marker panel (i.e. multiple biomarkers, one test)

BRAF in Melanoma - Reflexively (i.e. prior to starting 1L treatment)

- Upon request (i.e. case by case after disease progression)

If reflexively – Sequential single gene (i.e. one biomarker, one test)

4. ALK

EGFR

PDL-1

5. PCR

N/A to ALK/PDL1

6. N/A to ALK/PDL1

7. N/A to ALK/PDL1

8. Yes

9. ALK

Please specify number: 21 Average (per month)

EGFR

Please specify number: 21 Average (per month)

PDL-1

Please specify number: 21 Average (per month)

BRAF

Please specify number: 12 Average (per month)

10. On-site

11. <1 yr

12. 1 – 2 weeks

13. Individual funding through high cost medicines and procedures provision